TBPH Stock Analysis: Buy, Sell, or Hold?
TBPH - Theravance Biopharma, Inc.
$17.27
0.30 (1.77%)
▲
5d:
+3.48%
30d:
+5.5%
90d:
+15.91%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When TBPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TBPH trades at premium valuation expecting 5.5% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: TBPH trades at premium valuation expecting 5.5% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$28.59
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$17.75
2.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TBPH is currently trading at $17.27, which is considered extended relative to its 30-day fair value range of $16.06 to $16.72. From a valuation perspective, the stock is trading at a premium (Forward PE: 13.8) compared to its historical average (11.7). At these levels, the market is pricing in 5.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TBPH is in a downtrend. The price is approaching resistance at $17.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TBPH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TBPH is in a downtrend. The price is approaching resistance at $17.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TBPH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$16.06 -
$16.72
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
56.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($17.40)
- NEUTRAL: Trading at premium valuation - market expects 5.5% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$16.06 -
$16.72
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$16.21
Resistance Level
$17.67
Current Trend
Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.76
Wall Street Target
$17.40
(+0.8%)
Revenue Growth (YoY)
15.0%
Profit Margin
104.3%
Valuation Premium vs History
+5.5% premium
PE vs Historical
13.8 vs 11.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.5%
(market-implied from PE analysis)
1-Year Target
$18.22
(+6%)
2-Year Target
$19.22
(+11%)
3-Year Target
$20.28
(+17%)
3-Yr Target (if PE normalizes)
(PE: 14→12)
PE COMPRESSION
$17.24
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 497.6%)
$92.25
(+434%)
Base:
(SPY PE: 13.8, Growth: 497.6%)
$58.29
(+238%)
Bear:
(PE: 11.7, Growth: 497.6%)
$49.54
(+187%)
📈
Valuation based on Current Earnings
Trailing PE: 7.43 | Current EPS (TTM): $2.23
Bull Case
$10.25
(-40%)
Analyst growth -43.7%, PE expands to 8.2
Base Case
$9.32
(-45%)
Market implied -43.7%, PE stable at 7.4
Bear Case
$11.26
(-34%)
Severe decline -20.0%, PE contracts to 6.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 5:39 PM ET
Data refreshes hourly during market hours. Next update: 6:39 PM
Data refreshes hourly during market hours. Next update: 6:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TBPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Rhonda Farnum
SELL
31067 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 60 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 69 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
